Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow growth accelerates

Q3 FY2026 free cash flow of $19.71M (cash outflow) rose 81.0% year over year, ahead of the +40.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 12.3% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +81.0% holds above the trailing-twelve-month pace of +40.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$19.71M+12.3% QoQ
Last fiscal yearDec 2025
-$42.1M+10.0% YoY
LTMSep 2026
-$61.69M+40.1% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+81.0%——
1 year+10.0%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(42.1M) USD
Year-over-year change
-10.0%

Free Cash Flow vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +40.1% is the 5th highest of 9, against a peer median of +42.5%.
  • Over three fiscal years its annual growth of +14.1% compares with a peer median of +27.5%.
TRVI Competitors
Free Cash Flow for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$268.74M USD+732.4%—244.8%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 225.86M SEK-31.6%+7.4%16982.6%
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$174.39M USD-6.8%—15.3%
UPBUpstream Bio, Inc.LTM Mar 2026$140.01M USD+68.1%+91.1%4214.6%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.71M USD+16.8%+192.3%403.5%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$61.69M USD+40.1%+14.1%—
LQDALiquidia CorporationLTM Jun 2026$60.51M USD+148.8%+11.1%13.4%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$38.8M USD-77.0%-9.0%55.7%
TENXTenax Therapeutics, Inc.LTM Mar 2026$38.14M USD+129.6%+43.9%—
Peer median (excluding TRVI) —+42.5%+27.5%244.8%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Depreciation & Amortization50K43K123K147K144K
Deferred Income Tax(82K)0000
Stock-Based Compensation2.54M2.33M2.25M3.59M5.19M
Change in Working Capital1.51M(1.23M)(3.85M)6.83M(3.49M)
Accounts Receivables00000
Inventory00000
Accounts Payables831K9K(1.05M)1.61M(598K)
Other Working Capital678K(1.24M)(2.8M)5.22M(2.89M)
Other Non-Cash Items974K(162K)(1.17M)(907K)(1.17M)
Operating Cash Flow(28.95M)(28.18M)(31.71M)(38.26M)(42.09M)
Capital Expenditures0(159K)(137K)(35K)(12K)
Acquisitions (Net)0(829K)000
Purchases of Investments0(126.22M)(9.93M)(98.46M)(170.66M)
Sales of Investments019M69.5M75.6M74.93M
Other Investing Activities0829K01.37M1.64M
Investing Cash Flow0(107.37M)59.43M(21.53M)(94.11M)
Debt Repayment(68K)(5.83M)(9.41M)(126K)0
Common Stock Issued21.18M105.41M1.71M61.15M120.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(340K)11.73M(211K)464K714K
Financing Cash Flow20.78M111.31M(7.91M)61.48M121.01M
Effect of Forex Changes00000
Net Change in Cash(8.17M)(24.24M)19.81M1.7M(15.18M)
Free Cash Flow(28.95M)(28.33M)(31.85M)(38.29M)(42.1M)

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.